Cover Image
市場調查報告書

癌症的T細胞免疫療法:開發平台分析

T-Cell Immunotherapy for Cancer - Pipeline Analysis

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 367269
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
癌症的T細胞免疫療法:開發平台分析 T-Cell Immunotherapy for Cancer - Pipeline Analysis
出版日期: 2016年08月01日 內容資訊: 英文 75 Pages
簡介

全球癌症發病數量,2012年達到1400萬件,預計2030年達2100萬件。由於治療方法 (化療,放射治療等)的演進,可控制腫瘤的進展,不過,能完全治癒疾病本身的手法至今仍未開發出來。還有,也存留著各種副作用的問題 (噁心,毛髮損失等) 。為了應對那樣的問題,而進行了癌症的免疫療法 - T細胞免疫療法 - 的開發。

本報告提供癌症治療的T細胞免疫療法的現狀與未來性相關分析,T細胞免疫療法概要和目前技術水準,有利用可能性的主要領域,主要的推動及阻礙市場要素,今後的技術開發的可能性,市場機會預測,相關企業簡介等的調查評估。

第1章 分析師的見解

第2章 分析方法

第3章 簡介

第4章 市場動態

  • 推動市場要素
    • 投資、資金提供的數量增加
    • 技術進步
    • 強力且富有市場機會的開發中產品
    • 企業、非營利組織間的產業合作
    • 研究相關活動的活躍
    • 創業投資的融資
  • 課題
    • 在製造方面、規定方面的課題
    • 製造成本高,和對規模擴充性的要求
    • 在CD19+血液腫瘤以外的CAR-T細胞療法的有效性的限制
  • 市場機會
    • Juno Therapeutics、Kite Pharma、Novartis:巨大的市場機會的提供
    • 不久的將來CAR-T細胞療法達成大幅度成長的可能性

第5章 T細胞療法主要的治療領域

  • 血液腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固態腫瘤
    • 黑色素瘤
    • 膀胱癌
    • 腎臟癌
    • 卵巢癌
    • 乳癌
    • 肺癌

第6章 開發平台分析

第7章 T細胞免疫療法的投資

第8章 主要企業分析

  • Adaptimmune Therapeutics plc
  • Juno Therapeutics, Inc.
  • Kite Pharma, Inc.
  • Novartis International AG
  • Tessa Therapeutics Pte Ltd.
  • Gradalis, Inc.
  • Immunovative Therapies, Ltd.
  • Lion Biotechnologies, Inc.
  • Atara Biotherapeutics, Inc.
  • Celgene Corporation
  • Cellular Biomedicine Group
  • GlaxoSmithKline plc.
  • Immunocore Ltd.
  • Cell Medica
  • Inovio Pharmaceuticals, Inc.

圖表一覽

目錄

Cancer is a leading cause of death worldwide. According to GLOBOCAN 2012, the incidence of cancer is expected to increase from 14 Million in 2012 to approximately 21 Million by 2030. Although conventional therapies, such as chemotherapy and radiotherapy, have been the roots to slow down the progression of tumors, however till date no complete treatment of this disease is available in the market. Furthermore, these conventional therapies have numerous side-effects associated with them, such as nausea, hair loss and abnormal blood cell counts. These limitations and adverse effects of conventional therapies have therefore created a significant need for the treatment of cancer. This led to development of new therapies to curb the prevalence of this disease with minimal side-effects. One such therapy is cancer immunotherapy, particularly T-cell immunotherapy. T-cell immunotherapy has shown great promise in the treatment of patients with late-stage cancer.

According to RNCOS' new research report “T-Cell Immunotherapy for Cancer - Pipeline Analysis”, T-cell immunotherapy is one of the most widely researched fields in the recent years. The high potential of T-cell based therapies to cure various types of cancer indications makes it a popular research area. Numerous researches are being performed across the globe to explore the potential of T-cell immunotherapy for the treatment of different therapeutic areas. The rapidly expanding field of T-cell immunotherapy has experienced clinical successes along with some critical issues. T-cell immunotherapy has emerged as one of the innovative and potent arm of the Immunotherapeutics market.

The report provides an in-depth study on the current state of the T-Cell Immunotherapy industry. Currently, there is no commercialized T-cell immunotherapy; however due to high venture capitalist investments and increasing research related activities, this market is slated to witness a precipitous growth in the coming years. The report provides detailed analysis of various other factors affecting the growth of the market.

The report also covers the global as well as regional prevalence of major types of cancer for which T-cell immunotherapy is used. These cancers include leukemia, lymphoma, melanoma, ovarian cancer, and bladder cancer amongst others. This will help the companies to gain knowledge regarding the target population for various immunotherapies globally, and at regional level.

The report also provides detailed pipeline analysis of T-cell immunotherapy. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the T-cell immunotherapy market, such as phases, geographies, vectors used, therapeutic indications, technology types, and key players. The segment also covers the list of the key ongoing clinical trials along with their clinical phases. According to the research, CAR-T is the most widely used technology by the companies. Moreover, the report also suggests that most of the T-cell immunotherapies are in the research or pre-clinical phase. Limited number of therapies has been able to cross Phase I of the clinical trials.

Several companies and academic institutions are operating in this market with a focus on developing T-cell immunotherapy for ‘difficult to treat' cancers. These companies are also receiving various funding, grants, and investment from non-industry participants, and other companies and venture capitalist firms, which are aiding them to develop new products. The report provides details about major venture capitalist investments, government grants, and IPO raised in this market.

Finally, with a view to understanding the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global T-cell Immunotherapy market. The profiles of these companies include business overview, financials, product pipeline, and their strength and weakness analysis. Major players operating in the T-cell Immunotherapy market are Adaptimmune Therapeutics plc, Juno Therapeutics, Inc., Kite Pharma, Inc., Novartis International AG, Tessa Therapeutics Pte Ltd., Gradalis, Inc., Immunovative Therapies, Ltd., Lion Biotechnologies, Inc., Atara Biotherapeutics, Inc., Celgene Corporation, Cellular Biomedicine Group, GlaxoSmithKline plc, Immunocore Ltd., Cell Medica, and Inovio Pharmaceuticals, Inc.

Table of Contents

1. Analyst View

2. Research Methodology

3. Introduction

4. Market Dynamics

  • 4.1. Market Drivers
    • 4.1.1. Increasing Number of Investments and Grants
    • 4.1.2. Technological Advancements
    • 4.1.3. Robust and Opportunistic Pipeline
    • 4.1.4. Collaboration Amongst Industry Players and Non-Industry Participants
    • 4.1.5. Rising Research Related Activities
    • 4.1.6. Venture Capitalist Funding
  • 4.2. Challenges
    • 4.2.1. Manufacturing and Regulatory Challenges
    • 4.2.2. High Cost of Manufacturing Coupled With Demand for Scalability
    • 4.2.3. Limited Validation of CAR-T Therapy Outside Of CD19+ Hematological Malignancies
  • 4.3. Opportunities
    • 4.3.1. Juno Therapeutics, Kite Pharma, Novartis Offering Great Opportunities
    • 4.3.2. CAR-T Therapies Are Likely To Gain Momentum in Near Future

5. Major Therapeutic Areas for T-Cell Therapies

  • 5.1. Hematological Malignancies
    • 5.1.1. Leukemia
    • 5.1.2. Lymphoma
    • 5.1.3. Multiple Myeloma
  • 5.2. Solid Tumours
    • 5.2.1. Melanoma
    • 5.2.2. Bladder Cancer
    • 5.2.3. Kidney Cancer
    • 5.2.4. Ovarian Cancer
    • 5.2.5. Breast Cancer
    • 5.2.6. Lung Cancer

6. Pipeline Analysis

7. Investments in T-Cell Immunotherapy

8. Key Player Analysis

  • 8.1. Adaptimmune Therapeutics plc
  • 8.2. Juno Therapeutics, Inc.
  • 8.3. Kite Pharma, Inc.
  • 8.4. Novartis International AG
  • 8.5. Tessa Therapeutics Pte Ltd.
  • 8.6. Gradalis, Inc.
  • 8.7. Immunovative Therapies, Ltd.
  • 8.8. Lion Biotechnologies, Inc.
  • 8.9. Atara Biotherapeutics, Inc.
  • 8.10. Celgene Corporation
  • 8.11. Cellular Biomedicine Group
  • 8.12. GlaxoSmithKline plc.
  • 8.13. Immunocore Ltd.
  • 8.14. Cell Medica
  • 8.15. Inovio Pharmaceuticals, Inc.

List of Figures:

  • Figure 5-1: Global - Breakup of Cancer Prevalence by Region (%), 2015
  • Figure 5-2: Global - Breakup of Cancer Prevalence by Region (%), 2025
  • Figure 6-1: Global - T-Cell Immunotherapy Pipeline Analysis by Vectors (%), 2016
  • Figure 6-2: Global - T-Cell Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 6-3: Global - T-Cell Immunotherapy Pipeline Analysis by Therapeutic Indication (%), 2016
  • Figure 6-4: Global - T-Cell Immunotherapy Pipeline Analysis by Technology (%), 2016
  • Figure 6-5: Global - T-Cell Immunotherapy Pipeline Analysis by Key Players (%), 2016
  • Figure 6-6: Global - T-Cell Immunotherapy Pipeline Analysis by Geography (%), 2016

List of Tables:

  • Table 4-1: Global - Major Investments & Grants in T-Cell Immunotherapy (Million US$)
  • Table 5-1: Global - Cancer Prevalence (Million), 2015 & 2025
  • Table 5-2: Global - Leukemia Prevalence ('000), 2015 & 2025
  • Table 5-3: North America - Leukemia Prevalence ('000), 2015 & 2025
  • Table 5-4: Europe - Leukemia Prevalence ('000), 2015 & 2025
  • Table 5-5: Asia-Pacific - Leukemia Prevalence ('000), 2015 & 2025
  • Table 5-6: Rest of the World - Leukemia Prevalence ('000), 2015 & 2025
  • Table 5-7: Global - Lymphoma Prevalence ('000), 2015 & 2025
  • Table 5-8: North America - Lymphoma Prevalence ('000), 2015 & 2025
  • Table 5-9: Europe - Lymphoma Prevalence ('000), 2015 & 2025
  • Table 5-10: Asia-Pacific - Lymphoma Prevalence ('000), 2015 & 2025
  • Table 5-11: Rest of the World - Lymphoma Prevalence ('000), 2015 & 2025
  • Table 5-12: Global - Multiple Myeloma Prevalence ('000), 2015 & 2025
  • Table 5-13: North America - Multiple Myeloma Prevalence ('000), 2015 & 2025
  • Table 5-14: Europe - Multiple Myeloma Prevalence ('000), 2015 & 2025
  • Table 5-15: Asia-Pacific - Multiple Myeloma Prevalence ('000), 2015 & 2025
  • Table 5-16: Rest of the World - Multiple Myeloma Prevalence ('000), 2015 & 2025
  • Table 5-17: Global - Melanoma Prevalence ('000), 2015 & 2025
  • Table 5-18: North America - Melanoma Prevalence ('000), 2015 & 2025
  • Table 5-19: Europe - Melanoma Prevalence ('000), 2015 & 2025
  • Table 5-20: Asia-Pacific - Melanoma Prevalence ('000), 2015 & 2025
  • Table 5-21: Rest of the World - Melanoma Prevalence ('000), 2015 & 2025
  • Table 5-22: Global - Bladder Cancer Prevalence ('000), 2015 & 2025
  • Table 5-23: North America - Bladder Cancer Prevalence ('000), 2015 & 2025
  • Table 5-24: Europe - Bladder Cancer Prevalence ('000), 2015 & 2025
  • Table 5-25: Asia-Pacific - Bladder Cancer Prevalence ('000), 2015 & 2025
  • Table 5-26: Rest of the World - Bladder Cancer Prevalence ('000), 2015 & 2025
  • Table 5-27: Global - Kidney Cancer Prevalence ('000), 2015 & 2025
  • Table 5-28: North America - Kidney Cancer Prevalence ('000), 2015 & 2025
  • Table 5-29: Europe - Kidney Cancer Prevalence ('000), 2015 & 2025
  • Table 5-30: Asia-Pacific - Kidney Cancer Prevalence ('000), 2015 & 2025
  • Table 5-31: Rest of the World - Kidney Cancer Prevalence ('000), 2015 & 2025
  • Table 5-32: Global - Ovarian Cancer Prevalence ('000), 2015 & 2025
  • Table 5-33: North America - Ovarian Cancer Prevalence ('000), 2015 & 2025
  • Table 5-34: Europe - Ovarian Cancer Prevalence ('000), 2015 & 2025
  • Table 5-35: Asia-Pacific - Ovarian Cancer Prevalence ('000), 2015 & 2025
  • Table 5-36: Rest of the World - Ovarian Cancer Prevalence ('000), 2015 & 2025
  • Table 5-37: Global - Breast Cancer Prevalence ('000), 2015 & 2025
  • Table 5-38: North America - Breast Cancer Prevalence ('000), 2015 & 2025
  • Table 5-39: Europe - Breast Cancer Prevalence ('000), 2015 & 2025
  • Table 5-40: Asia-Pacific - Breast Cancer Prevalence ('000), 2015 & 2025
  • Table 5-41: Rest of the World - Breast Cancer Prevalence ('000), 2015 & 2025
  • Table 5-42: Global - Lung Cancer Prevalence ('000), 2015 & 2025
  • Table 5-43: North America - Lung Cancer Prevalence ('000), 2015 & 2025
  • Table 5-44: Europe - Lung Cancer Prevalence ('000), 2015 & 2025
  • Table 5-45: Asia-Pacific - Lung Cancer Prevalence ('000), 2015 & 2025
  • Table 5-46: Rest of the World - Lung Cancer Prevalence ('000), 2015 & 2025
  • Table 6-1: Global T-Cell Immunotherapy Pipeline
  • Table 7-1: Global - Major Venture Capitalist Investment in T-Cell Immunotherapy
  • Table 7-2: Global - Major IPO Raised in T-Cell Immunotherapy (Million US$), 2014-2016
  • Table 8-1: Adaptimmune Therapeutics plc - Total Revenue (Million US$), FY 2014 & FY 2015
  • Table 8-2: Adaptimmune Therapeutics plc - T-Cell Immunotherapy Pipeline
  • Table 8-3: Juno Therapeutics, Inc. - Total Revenue (Million US$), 2015
  • Table 8-4: Juno Therapeutics, Inc. - T-Cell Immunotherapy Pipeline
  • Table 8-5: Kite Pharma, Inc. - Total Revenue (Million US$), 2015
  • Table 8-6: Kite Pharma, Inc. - T-Cell Immunotherapy Pipeline
  • Table 8-7: Novartis - Net Sales (Million US$), 2013, 2014 & 2015
  • Table 8-8: Novartis - T-Cell Immunotherapy Pipeline
  • Table 8-9: Tessa Therapeutics Pte Ltd. - T-Cell Immunotherapy Pipeline
  • Table 8-10: Gradalis, Inc. - T-Cell Immunotherapy Pipeline
  • Table 8-11: Immunovative Therapies, Ltd. - T-Cell Immunotherapy Pipeline
  • Table 8-12: Lion Biotechnologies, Inc. - T-Cell Immunotherapy Pipeline
  • Table 8-13: Atara Biotherapeutics, Inc. - T-Cell Immunotherapy Pipeline
  • Table 8-14: Celgene Corporation - Total Revenue (Million US$), 2013, 2014 & 2015
  • Table 8-15: Celgene Corporation - T-Cell Immunotherapy Pipeline
  • Table 8-16: Cellular Biomedicine Group - Total Revenue (Million US), 2013, 2014 & 2015
  • Table 8-17: Cellular Biomedicine Group - T-Cell Immunotherapy Pipeline
  • Table 8-18: GlaxoSmithKline plc. - Group Turnover (Million US$), 2013, 2014 & 2015
  • Table 8-19: GlaxoSmithKline plc. - T-Cell Immunotherapy Pipeline
  • Table 8-20: Immunocore Ltd. - T-Cell Immunotherapy Pipeline
  • Table 8-21: Cell Medica - T-Cell Immunotherapy Pipeline
  • Table 8-22: Inovio Pharmaceuticals, Inc. - Revenue (Million US$), 2013, 2014 & 2015
  • Table 8-23: Inovio Pharmaceuticals, Inc. - T-Cell Immunotherapy Pipeline
Back to Top